


Product Name	: MLN1117
Synonyms	: INK1117;TAK-117;TAK117;Serabelisib;INK 1117
Cat No.	: M11125
CAS Number	: 1268454-23-4
Molecular Formula	: C ₁₉ H ₁₇ N ₅ O ₃
Formula Weight	: 363.37
Chemical Name	: Methanone, [6-(2-amino-5-benzoxazolyl)imidazo[1,2-a]pyridin-3-yl]-4-morpholinyl-
Description	MLN1117 (INK1117, TAK-117, Serabelisib) is a potent, selective PI3K p110α inhibitor with IC₅₀ of 15 nM, displays >300-fold selectivity over p110β/γ/δ and mTOR; inhibits AKT phosphorylation and growth in PIK3CA mutant breast cancer cells with IC₅₀ of 2 μM, significantly suppresses B cell proliferation driven by anti-IgM alone but not by anti-IgM plus IL-4; abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma combined with alisertib. Breast Cancer Phase 2 Clinical
Pathway	: PI3K/Akt/mTOR signaling
Target	: PI3K
Receptor	: mTOR;p110α;p110β;p110γ;p110δ
Solubility	: DMSO: 6.4 mg/mL (Need ultrasonic or warming)
SMILES	: <chem>O=C(C1=CN=C2C=CC(C3=CC=C(OC(N)=N4)C4=C3)=CN21)N5CCOCC5</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:



1. So L, et al. J Biol Chem. 2013 Feb 22;288(8):5718-31. | 2. Juric D, et al. Clin Cancer Res. 2017 Sep 1;23(17):5015-5023. | 3. Islam S, et al. Oncotarget. 2017 Nov 1;8(59):100326-100338. | 4. Yea SS, et al. PLoS One. 2014 Jun 10;9(6):e99486.